COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer

Up-regulation of connexin 32 gene by 5-aza-2′-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling

(2010) Y. Takano et al.   BIOCHEMICAL PHARMACOLOGY

Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line

(2009) Karnati R. Roy et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB

(2009) H. Bark et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Celecoxib enhanced the sensitivity of cancer cells to anticancer drugs by inhibition of the expression of P-glycoprotein through a COX-2-Independent Manner

(2009) Wenhong Xia et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

JWA Sensitizes P-Glycoprotein-Mediated Drug-Resistant Choriocarcinoma Cells to Etoposide VIA JNK and Mitochondrial-Associated Signal Pathway

(2009) Yan Zhang et al.   JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES

Enhancement of Doxorubicin Cytotoxicity on Human Esophageal Squamous Cell Carcinoma Cells by Indomethacin and 4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC236) via Inhibiting P-Glycoprotein Activity

(2009) L. Yu et al.   MOLECULAR PHARMACOLOGY

COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats

(2009) Erwin A. van Vliet et al.   NEUROPHARMACOLOGY

Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding

(2009) S. G. Aller et al.   SCIENCE

Is resistance useless? Multidrug resistance and collateral sensitivity

(2009) Matthew D. Hall et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer

(2008) K Kawasaki et al.   CANCER GENE THERAPY

c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia

(2008) E D Lagadinou et al.   LEUKEMIA